Progression free survival is superior with alemtuzumab vs chlorambucil as front-line therapy for patients with B-cell chronic lymphocytic leukemia

被引：0
|
作者：
Hillmen, P.
Skotnicki, A.
Robak, T.
Jaksic, B.
Sirard, C.
Mayer, J.
机构：
[1] Leeds Gen Infirm, Leeds, W Yorkshire, England
[2] Jagiellonian Univ, Coll Med, Krakow, Poland
[3] Kopernik Mem Hosp, Lodz, Poland
[4] Univ Zagreb, Clin Hosp Merkur, Zagreb, Croatia
[5] GENZYME, Cambridge, MA USA
[6] Univ Hosp Brno, Brno, Czech Republic
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0127
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [31] Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia
    Vitale, Candida
    Ciccone, Maria
    Hinojosa, Christina
    Keating, Michael
    Pemmaraju, Naveen
    O'Brien, Susan
    Wierda, William
    Thomas, Deborah A.
    Borthakur, Gautam
    Ohanian, Maro
    Burger, Jan A.
    Ferrajoli, Alessandra
    BLOOD, 2015, 126 (23)
  • [32] Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience
    Spunarova, Michaela
    Tom, Nikola
    Pavlova, Sarka
    Mraz, Marek
    Brychtova, Yvona
    Doubek, Michael
    Panovska, Anna
    Francova, Hana Skuhrova
    Brzobohata, Anna
    Pospisilova, Sarka
    Mayer, Jiri
    Trbusek, Martin
    LEUKEMIA RESEARCH, 2019, 81 : 75 - 81
  • [33] Ofatumumab as front-line treatment in elderly unfit patients with chronic lymphocytic leukemia
    Vitale, Candida
    Ciccone, Maria
    Hinojosa, Christina
    Keating, Michael J.
    Pemmaraju, Naveen
    O'Brien, Susan
    Wierda, William G.
    Thomas, Deborah H.
    Borthakur, Gautam
    Ohanian, Maro
    Burger, Jan A.
    Ferrajoli, Alessandra
    LEUKEMIA & LYMPHOMA, 2015, 56 : 144 - 145
  • [34] Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia
    Christodoulopoulos, G
    Malapetsa, A
    Schipper, H
    Golub, E
    Radding, C
    Panasci, LC
    CLINICAL CANCER RESEARCH, 1999, 5 (08) : 2178 - 2184
  • [35] Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
    Mauro, Francesca R.
    Molica, Stefano
    Laurenti, Luca
    Cortelezzi, Agostino
    Carella, Angelo M.
    Zaja, Francesco
    Chiarenza, Annalisa
    Angrilli, Francesco
    Nobile, Francesco
    Marasca, Roberto
    Musolino, Caterina
    Brugiatelli, Maura
    Piciocchi, Alfonso
    Vignetti, Marco
    Fazi, Paola
    Gentile, Giuseppe
    De Propris, Maria S.
    Della Starza, Irene
    Marinelli, Marilisa
    Chiaretti, Sabina
    Del Giudice, Ilaria
    Nanni, Mauro
    Albano, Francesco
    Cuneo, Antonio
    Guarini, Anna
    Foa, Robin
    LEUKEMIA RESEARCH, 2014, 38 (02) : 198 - 203
  • [36] Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia
    Ansstas, George
    Vij, Ravi
    LEUKEMIA & LYMPHOMA, 2012, 53 (07) : 1273 - 1281
  • [37] Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Elter, Thomas
    Kilp, Julia
    Borchmann, Peter
    Schulz, Holger
    Hallek, Michael
    Engert, Andreas
    Haematologica-The Hematology Journal, 2009, 94 (01): : 150 - 152
  • [38] Impact on Progression Free Survival of Autologous Stem Cell transplantation after Consolidation with Alemtuzumab in Chronic Lymphocytic Leukemia
    Montillo, Marco
    Ricci, Francesca
    Tedeschi, Alessandra
    Miqueleiz, Sara
    Grillo, Giovanni
    Vismara, Eleonora
    Greco, Antonino
    Veronese, Silvio
    Morra, Enrica
    BLOOD, 2008, 112 (11) : 761 - 761
  • [39] Maintenance alemtuzumab in refractory B-cell chronic lymphocytic leukemia patients: Updated data.
    Thieblemont, C
    Houot, R
    Toure, BA
    Traulle, C
    Michallet, AS
    Bouafia, F
    Espinouse, D
    Salles, G
    Coiffier, B
    BLOOD, 2005, 106 (11) : 340B - 340B
  • [40] Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Ricci, Francesca
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Morra, Enrica
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 41 - 52
12345